Rodica Pop-Busui, MD, PhD, is the Larry D. Soderquist Professor of Diabetes, and a recognized national and international leader in the field of diabetes and diabetes complications. She is the Vice Chair for Clinical & Health Outcomes Research in the Department of Internal Medicine, and Director of Clinical Research, Mentoring and Development of the Caswell Diabetes Institute at the University of Michigan. Her research interests involve chronic complications of diabetes, particularly diabetic peripheral and cardiovascular autonomic neuropathy, diabetic foot complications, diabetic kidney disease and cardiovascular disease, and the design and conduct of traditional and pragmatic clinical trials in diabetes and diabetes complications.
She has been PI and member of the Steering Committee in several landmark diabetes clinical trials including: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications,  Preventing Early Renal Loss in Type 1 Diabetes (PERL), Bypass Angioplasty Revascularization Diabetes 2 (BARI- 2D) and Glycemia Reduction Approaches in Type 2 Diabetes-A Comparative Effectiveness Study (GRADE). She designed and leads several investigator-initiated studies funded by NIDDK and Pharma to unveil disease modifying agents for diabetic neuropathy and other chronic diabetes complications. 
Dr Pop-Busui is the corresponding principal investigator and member of the Steering Committee of the recently established NIDDK Diabetes Foot Consortium and one of the principal investigators of the JDRF Center of Excellence at the University of Michigan .
Dr. Pop-Busui has published more than 220 peer-reviewed manuscripts and book chapters, and received awards from the Fulbright Foundation, American Diabetes Association (ADA) and the University of Michigan. She has chaired the 2017 ADA Position Statement on Diabetic Neuropathy, has served as Chair of the ADA Scientific Research Review Clinical, Chair of the ADA Diabetes & Cardiovascular Disease Interest Group, and chairs the Precision Prognostic in Type 1 Diabetes Working Group of the ADA/EASD. She is now the President for Medicine and Science of the American Diabetes Association.